[ad_1]
The acquired brands symbolize two varieties of merchandise, (a) mometasone mono product and (b) mixture of mometasone with azelastine, and are indicated for the therapy of Seasonal and Perennial Allergic Rhinitis.
M V Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets) of Dr. Reddy’s stated, “The new brands are a great addition to our product portfolio in Russia, Ukraine, Kazakhstan and Uzbekistan which are important core markets for us. Momat Rino, the largest brand acquired, has recently received OTC registration in Russia and this will enable accelerated access of this product to patients. The acquired products will further add to Dr. Reddy’s strong presence in the anti-allergy segment in these countries, and will also enable us to offer a more comprehensive solution to patients in this area.”
(This story has not been edited by Newslivenation workers and is auto-generated from a syndicated feed.)